ADELAIDE, Australia and CAMBRIDGE, Mass. – Bionomics Limited (NASDAQ:BNOX), a clinical-stage biotechnology company, has announced its participation in the prestigious Biotech Showcase™ 2024 event. On January 9, 2024, Bionomics will present an update on its leading asset, BNC210, a Phase 3 ready α7 nicotinic receptor negative allosteric modulator, which has the potential to revolutionize the treatment of social anxiety disorder and post-traumatic stress disorder.
The Company’s President and CEO, Spyros Papapetropoulos, M.D., Ph.D., will provide insights into the latest progress of BNC210 and shed light on its promising potential. The presentation is scheduled for 4:30 PM PST at the Hilton San Francisco – Union Square, in Yosemite A.
As part of the event, Bionomics’ management will also be available for one-on-one meetings with registered investors and potential partners. Additionally, the company is set to host individual meetings in San Francisco during JP Morgan week.
Bionomics is renowned for its development of novel and first-in-class allosteric ion channel modulators designed to address serious central nervous system disorders that have significant unmet medical needs. The company’s breakthrough drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor. It has shown great promise for the acute treatment of Social Anxiety Disorder (SAD) and the chronic treatment of Post-Traumatic Stress Disorder (PTSD).
Beyond BNC210, Bionomics proudly boasts a strategic partnership with Merck & Co., Inc., known as MSD outside the United States and Canada. This collaboration has produced two drugs, currently in early-stage clinical trials, aiming to tackle cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Furthermore, Bionomics’ pipeline includes several preclinical assets specifically targeting Kv3.1/3.2 and Nav1.7/1.8 ion channels. These innovative developments seek to address critical CNS conditions that are currently marked by significant unmet medical needs.
To address risks and uncertainties, Bionomics wishes to caution investors that any statements made in this press release that do not refer to historical facts are deemed forward-looking statements. The Company reminds investors that these statements involve inherent risks and uncertainties that could alter the outcome or progression of its plans.
Bionomics urges investors and readers to approach forward-looking statements with caution, as actual results may differ materially from those expressed or implied in such statements. The Company does not assume any obligation to update or revise this news release to reflect any changes that may occur after the date hereof.
For additional information regarding risks and uncertainties, investors are advised to refer to Bionomics’ filings with the Securities and Exchange Commission (SEC) and to visit the SEC’s website (www.sec.gov) or Bionomics’ website (www.bionomics.com.au) under the Investor Center section.
As Bionomics prepares to present at Biotech Showcase™ 2024, the global biotechnology community eagerly awaits updates on BNC210, anticipating significant advancements in the treatment of social anxiety disorder and post-traumatic stress disorder. With patient well-being at the forefront, Bionomics continues to pave the way for groundbreaking developments in the field of central nervous system disorders.
